Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.
2.

Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.

Jia H, Pallos J, Jacques V, Lau A, Tang B, Cooper A, Syed A, Purcell J, Chen Y, Sharma S, Sangrey GR, Darnell SB, Plasterer H, Sadri-Vakili G, Gottesfeld JM, Thompson LM, Rusche JR, Marsh JL, Thomas EA.

Neurobiol Dis. 2012 May;46(2):351-61.

3.

Identification of novel isoform-selective inhibitors within class I histone deacetylases.

Hu E, Dul E, Sung CM, Chen Z, Kirkpatrick R, Zhang GF, Johanson K, Liu R, Lago A, Hofmann G, Macarron R, de los Frailes M, Perez P, Krawiec J, Winkler J, Jaye M.

J Pharmacol Exp Ther. 2003 Nov;307(2):720-8. Epub 2003 Sep 15.

4.

Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin.

Hayashi A, Horiuchi A, Kikuchi N, Hayashi T, Fuseya C, Suzuki A, Konishi I, Shiozawa T.

Int J Cancer. 2010 Sep 1;127(6):1332-46. doi: 10.1002/ijc.25151.

5.

Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's disease.

Moumné L, Campbell K, Howland D, Ouyang Y, Bates GP.

PLoS One. 2012;7(2):e31080. doi: 10.1371/journal.pone.0031080. Epub 2012 Feb 8.

6.

Expression and functional characterization of recombinant human HDAC1 and HDAC3.

Li J, Staver MJ, Curtin ML, Holms JH, Frey RR, Edalji R, Smith R, Michaelides MR, Davidsen SK, Glaser KB.

Life Sci. 2004 Apr 16;74(22):2693-705.

PMID:
15043985
7.

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.

Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N, Finn PW, Collins LS, Tumber A, Ritchie JW, Jensen PB, Lichenstein HS, Sehested M.

Biochem J. 2008 Jan 15;409(2):581-9.

PMID:
17868033
8.

Histone modifiers and marks define heterogeneous groups of colorectal carcinomas and affect responses to HDAC inhibitors in vitro.

Lutz L, Fitzner IC, Ahrens T, Geißler AL, Makowiec F, Hopt UT, Bogatyreva L, Hauschke D, Werner M, Lassmann S.

Am J Cancer Res. 2016 Feb 15;6(3):664-76. eCollection 2016.

9.

Role of class I and class II histone deacetylases in carcinoma cells using siRNA.

Glaser KB, Li J, Staver MJ, Wei RQ, Albert DH, Davidsen SK.

Biochem Biophys Res Commun. 2003 Oct 17;310(2):529-36.

PMID:
14521942
10.

Therapeutic application of histone deacetylase inhibitors for central nervous system disorders.

Kazantsev AG, Thompson LM.

Nat Rev Drug Discov. 2008 Oct;7(10):854-68. doi: 10.1038/nrd2681. Review.

PMID:
18827828
11.

Individual histone deacetylases in Drosophila modulate transcription of distinct genes.

Cho Y, Griswold A, Campbell C, Min KT.

Genomics. 2005 Nov;86(5):606-17. Epub 2005 Aug 31.

PMID:
16137856
12.

Histone deacetylase 3 as a novel therapeutic target in multiple myeloma.

Minami J, Suzuki R, Mazitschek R, Gorgun G, Ghosh B, Cirstea D, Hu Y, Mimura N, Ohguchi H, Cottini F, Jakubikova J, Munshi NC, Haggarty SJ, Richardson PG, Hideshima T, Anderson KC.

Leukemia. 2014 Mar;28(3):680-9. doi: 10.1038/leu.2013.231. Epub 2013 Aug 5.

13.

Histone deacetylase 1 (HDAC1) regulates histone acetylation, development, and gene expression in preimplantation mouse embryos.

Ma P, Schultz RM.

Dev Biol. 2008 Jul 1;319(1):110-20. doi: 10.1016/j.ydbio.2008.04.011. Epub 2008 Apr 18.

14.

Quantitative analysis of histone deacetylase-1 selective histone modifications by differential mass spectrometry.

Lee AY, Paweletz CP, Pollock RM, Settlage RE, Cruz JC, Secrist JP, Miller TA, Stanton MG, Kral AM, Ozerova ND, Meng F, Yates NA, Richon V, Hendrickson RC.

J Proteome Res. 2008 Dec;7(12):5177-86. doi: 10.1021/pr800510p.

PMID:
19367703
15.

Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.

Wang Y, Wallach J, Duane S, Wang Y, Wu J, Wang J, Adejare A, Ma H.

Drug Des Devel Ther. 2017 May 2;11:1369-1382. doi: 10.2147/DDDT.S124977. eCollection 2017.

16.

The Effects of Pharmacological Inhibition of Histone Deacetylase 3 (HDAC3) in Huntington's Disease Mice.

Jia H, Wang Y, Morris CD, Jacques V, Gottesfeld JM, Rusche JR, Thomas EA.

PLoS One. 2016 Mar 31;11(3):e0152498. doi: 10.1371/journal.pone.0152498. eCollection 2016.

17.

Development of histone deacetylase inhibitors for cancer treatment.

Marchion D, Münster P.

Expert Rev Anticancer Ther. 2007 Apr;7(4):583-98. Review.

PMID:
17428177
18.

A selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related tests.

Schroeder FA, Lewis MC, Fass DM, Wagner FF, Zhang YL, Hennig KM, Gale J, Zhao WN, Reis S, Barker DD, Berry-Scott E, Kim SW, Clore EL, Hooker JM, Holson EB, Haggarty SJ, Petryshen TL.

PLoS One. 2013 Aug 14;8(8):e71323. doi: 10.1371/journal.pone.0071323. eCollection 2013.

19.

Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer.

Wilson AJ, Byun DS, Popova N, Murray LB, L'Italien K, Sowa Y, Arango D, Velcich A, Augenlicht LH, Mariadason JM.

J Biol Chem. 2006 May 12;281(19):13548-58. Epub 2006 Mar 13.

20.

MS-275 inhibits aroclor 1254-induced SH-SY5Y neuronal cell toxicity by preventing the formation of the HDAC3/REST complex on the synapsin-1 promoter.

Formisano L, Guida N, Laudati G, Mascolo L, Di Renzo G, Canzoniero LM.

J Pharmacol Exp Ther. 2015 Feb;352(2):236-43. doi: 10.1124/jpet.114.219345. Epub 2014 Dec 2.

Supplemental Content

Support Center